426219-18-3

Basic information

• Product Name: TAK-700
• Synonyms: (S)-6-(7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-e]imidazol-7-yl)-N-methyl-2-naphthamide;6-[7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl]-N-methyl-2-naphthalenecarboxamide TAK-700 (Orteronel);6-(6,7-dihydro-7-hydroxy-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2-Naphthalenecarboxamide;6-(6,7-dihydro-7-hydroxy-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methy;6-[7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl]-N-methyl-2-naphthalenecarboxamide
• CAS NO: 426219-18-3
• Molecular Formula: C18H17N3O2
• Molecular Weight: 307.34648
• Product Categories: Inhibitors;Inhibitor
• Mol File: 426219-18-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TAK-700(CAS DataBase Reference)
• NIST Chemistry Reference: TAK-700(426219-18-3)
• EPA Substance Registry System: TAK-700(426219-18-3)

Safety Data

• Hazardous Substances Data: 426219-18-3(Hazardous Substances Data)

Usage

Uses

Used in Prostate Cancer Treatment:
TAK-700 is used as a therapeutic agent for the treatment of advanced prostate cancer. It functions by inhibiting the enzyme CYP17, which is crucial for androgen production. By reducing androgen levels, TAK-700 helps to slow down or stop the growth of prostate cancer cells.
Used in Clinical Trials for Other Hormone-Related Cancers:
TAK-700 is being evaluated in clinical trials for its potential application in treating other hormone-related cancers such as breast and ovarian cancer. Its mechanism of action, which involves the inhibition of androgen production, may also be beneficial in managing the growth of cancer cells in these types of malignancies.
Used in Pharmaceutical Research and Development:
TAK-700 serves as a subject of interest in pharmaceutical research and development for the discovery of new drugs targeting hormone production and action in cancer treatment. Its selective inhibition of CYP17 makes it a valuable compound for studying the role of androgens in cancer progression and for developing targeted therapies with fewer side effects.

Upstream product

• 426219-43-4 5,6-dihydro-7H-pyrrolo[1,2-c]imidazol-7-one 
• 566200-77-9 6-[1,3-dihydroxy-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl-2-naphthamide 
• 109-72-8 n-butyllithium 
• 1346155-60-9 6-(7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N,N-diisopropyl-2-naphthamide 
• 426219-35-4 6-bromo-N-methyl-2-naphthamide 
• 392-83-6 o-trifluoromethylphenyl bromide 
• 426219-46-7 6-bromo-N,N-diisopropyl-2-naphthamide 
• 1346155-54-1 N,N-diisopropyl-6-[1-hydroxy-1-(1-trityl-1H-imidazol-4-yl)methyl]-2-naphthamide 
• 426219-47-8 N,N-diisopropyl-6-[(1-trityl-1H-imidazol-4-yl)carbonyl]-2-naphthamide 
• 74-89-5 methylamine 
• 1346155-45-0 3-bromo-1-(1H-imidazol-4-yl)-1-propanone hydrobromide 
• 57531-35-8 C₆H₆N₂O 
• 5773-80-8 6-bromo-2-naphthoic acid 
• 87700-60-5 6-bromonaphthalene-2-carbonyl chloride 

Downstream Products

• 566939-85-3 Orteronel 
• 752243-39-3 6-(7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methylnaphthalene-2-carboxamide 
• 426219-53-6 2C₁₀H₁₁NO₅*C₁₈H₁₇N₃O₂ 

Relevant articles and documents

1,1-Diarylalkenes as anticancer agents: Dual inhibitors of tubulin polymerization and phosphodiesterase 4

A series of 1,1-diarylalkene derivatives were prepared to optimize the properties of CC-5079 (1), a dual inhibitor of tubulin polymerization and phosphodiesterase 4 (PDE4). By using the 3-ethoxy-4-methoxyphenyl PDE4 pharmacophore as one of the aromatic ri

RELEASE-CONTROL COMPOSITION

The present invention relates to a controlled release capsule preparation for oral administration, which contains (i) a granule containing a physiologically active substance which is a compound represented by the formula: wherein n is an integer of 1 to 3, and Ar is an aromatic ring optionally having substituent(s), or a salt thereof, and a hydrophilic polymer, and coated with an enteric coating agent and the like, and (ii) a fluidizer. According to the present invention, a controlled release composition for oral administration of an imidazole derivative, which has steroid C17,20-lyase inhibiting activity and which has remarkably improved sustainability of the blood concentration, is provided.

Novel imidazole derivatives, production method thereof and use thereof

The present invention provides a compound having a steroid C17,20-lyase-inhibitory activity and useful for the therapy and prophylaxis of tumor such as prostatism, breast cancer and the like, and a method for efficiently separating an optically active compound of this compound from a mixture of optical isomers thereof, a compound of the formula: wherein each symbol is as defined in the specification, a salt thereof or a prodrug thereof, and a method for obtaining an optically active compound by optically resolving a mixture of optical isomers by the use of a resolving agent such as tartranilic acid and the like.

PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME

The present invention provides an industrially advantageous process for producing a steroid C17,20 lyase inhibitor represented by the general formula (I): and a Reformatsky reagent in a stable form suitable for the process.In the present invention, a compound represented by the general formula (I) is produced by reducing a specific β-hydroxy ester compound derivative or a salt thereof obtained from a specific carbonyl compound in a Reformatsky reaction in the presence of a metal hydride complex and a metal halide, and then subjecting it to a ring-closing reaction. In the above Reformatsky reaction, it is useful to use a stable solution of a compound represented by the general formula BrZnCH2COOC2H5 or a crystal of the compound which is represented by the formula (BrZnCH2COOC2H5·THF)2.